Nikolay Runev

Prof. Dr. Nikolay Runev

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2021 in Medicina
Verified
Journal Article
Open access
PDF file
SNStefan Naydenov
Stefan Naydenov
NRNikolay Runev
Nikolay Runev
EMEmil Ivanov Manov
Emil Ivanov Manov
Background and Objectives: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. Materials and Methods: An open-label study aimed to investigate the prevalence of spontaneous echo contrast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. We included 51 consecutive patients (50.9% males), mean age 69.3 ± 7.4 years with paroxysmal/unknown duration of AF, considered for cardioversion, who agreed to have transesophageal echocardiography at enrollment and 3 weeks later. Results: At baseline SEC was present in 26 (50.9%) and LAT in 10 (19.6%) of 51 patients. After 3 weeks on DOAC, SEC persisted in 12 (25.0%) and LAT in 7 (14.5%) of 48 patients, p < 0.05 vs. baseline. Factors, associated most strongly with persistence of SEC/LAT, were left atrial appendage (LAA) emptying velocity 2 (OR = 1.84), and indexed left atrial volume ≥34 mL/m2 (OR = 1.37). Conclusions: In our study the incidence of SEC/LAT, particularly in AF with unknown duration, was not as low as we expected. The prevalence of SEC/LAT seemed to be dependent on factors not routinely evaluated in AF patients planned for cardioversion (indexed LA volume, LAA morphology and number of lobules, LAA emptying velocity, etc.). Our data suggested an individualized approach for DOAC duration in AF patients before an attempt for restoration of sinus rhythm is made, taking into consideration the LAA morphology and function.

25 May 2018 in Medicina
Verified
Journal Article
Open access
PDF file
SNStefan Naydenov
Stefan Naydenov
NRNikolay Runev
Nikolay Runev
EMEmil Ivanov Manov
Emil Ivanov Manov
DVDaniela Vasileva
Daniela Vasileva
YRYavor Rangelov
Yavor Rangelov
NNNadya Naydenova
Nadya Naydenova
Background and objectives: Atrial fibrillation (AF) is the most common arrhythmia worldwide and a major risk factor for cardiovascular complications. Our study aimed to investigate the prevalence, risk factors, demographics, co-morbidities and treatment of AF among in-hospital Bulgarian patients. Materials and Methods: A cross-sectional study including 1027 consecutive patients (n = 516, 50.2% males) with a mean age of 67.6 ± 11.3 years, hospitalized for any reason from 1 May until 31 December 2016 in one of the largest internal clinics in Bulgaria, was carried out. Results: Atrial fibrillation was diagnosed in 634 (61.7%) patients. The prevalence of modifiable AF risk factors was as follows: heart failure, 98.9%; arterial hypertension (HTN), 93.5%; valvular heart disease, 40.9%; chronic lung disease, 26.7%; type 2 diabetes mellitus, 24.9%; thyroid disease, 16.9%; and ischemic heart disease, 11.2%. Univariate logistic regression analysis identified the following risk factors with strongest impact on AF: left ventricular ejection fraction <40% (odds ratio (OR) = 1.951, 95% confidence interval (CI) 1.208–3.151), valvular heart disease (OR = 1.926, 95% CI 1.134–3.862), left ventricular ejection fraction 40–49% (OR = 1.743, 95% CI 1.248–3.017), HTN (OR = 1.653, 95% CI 1.092–3.458). History of ischemic stroke was present in 14.4% of the patients with AF. Oral antithrombotic drugs were prescribed to 85.7%: direct oral anticoagulants to 37.9%, vitamin K antagonists to 43.2%, and antiplatelets to 4.6%. Heart rate control medications and antiarrhythmics were prescribed to 75.4% and 40.2%, respectively. Conclusions: Atrial fibrillation was highly prevalent among our study population. Reduced and mid-range left ventricular ejection fraction, valvular heart disease, and HTN were the risk factors with the strongest association with AF. Although a large number of our AF patients were administered antithrombotic treatment, the prescription rate of oral anticoagulants should be further improved.

26 June 2019 in Medicina
Verified
Journal Article
Open access
PDF file
NRNikolay Runev
Nikolay Runev
TPTatjana Potpara
Tatjana Potpara
SNStefan Naydenov
Stefan Naydenov
AVAnita Vladimirova
Anita Vladimirova
GGGergana Georgieva
Gergana Georgieva
EMEmil Ivanov Manov
Emil Ivanov Manov
Background and Objectives: Oral anticoagulation (OAC) is widely used in daily clinical practice worldwide for various indications. We aimed to explore the perception of Bulgarian clinicians about their patients’ attitude and knowledge of long-term OAC, prescribed for atrial fibrillation (AF) and/or known deep venous thrombosis (DVT)/pulmonary embolism (PE). Materials and Methods: We performed a cross-sectional study that involved 226 specialists: 187 (82.7%) cardiologists, 23 (10.2%) neurologists, and 16 (7.1%) vascular surgeons. They filled in a questionnaire, specially designed for our study, answering various questions regarding OAC treatment in their daily clinical practice. Results: The mean prescription rate of OACs in AF patients was 80.3% and in DVT/PE—88.6%. One hundred and eighty-seven (82.7%) of the participants stated they see their patients on OAC at least once per month. According to more than one-third of the inquired clinicians, the patients did not understand well enough the provided information concerning net clinical benefit of OAC treatment. About 68% of the clinicians declared that their patients would prefer a “mutual” approach, discussing with the physician the OAC options and taking together the final decision, whereas according to 43 (19.0%), the patients preferred the physician to take a decision for them. Patients’ OAC treatment had been interrupted at least once within the last year due to a physician’s decision by 178 (78.8%) of the participants and the most common reason was elective surgery. The most influential factors for a patient’s choice of OAC were the need of a specific diet to be kept, intake frequency, and possible adverse reactions. Conclusions: Our results suggest that a clinician’s continuous medical education, shared decision-making, and appropriate local strategies for improved awareness of AF/DVT/PE patients are key factors for improvement of OAC management.

19 April 2021 in Preprints.org
Verified
Preprint
Open access
SNStefan Naydenov
Stefan Naydenov
EMEmil Manov
Emil Manov
NRNikolay Runev
Nikolay Runev
Background: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. Methods: An open-label study, aiming to investigate the prevalence of spontaneous echo con-trast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. We included 51 consecutive patients (50.9% males), mean age 69.3±7.4 years with paroxys-mal/unknown duration of AF, considered for cardioversion, who agreed to have transesophage-al echocardiography at enrollment and 3 weeks later. Results: At baseline SEC was present in 26 (50.9%) and LAT in 10 (19.6%) of 51 patients. After 3 weeks on DOAC, SEC persisted in 12 (25.0%) and LAT in 7 (14.5%) of 48 patients, p<0.05 vs base-line. Factors, associated most strongly with persistence of SEC/LAT were left atrial appendage (LAA) emptying velocity 2 (OR=1.84) and indexed left atrial volume ≥34 ml/m2 (OR=1.37). Conclusions: The recommended minimal period of 3 weeks of oral anticoagulation lead to SEC/LAT resolution in 47% of our patients. To our opinion, LA/LAA morphology and function should be taken into account when determining the duration of DOAC treatment before planned cardioversion.

26 May 2018 in Balkan Medical Journal
Verified
Journal Article
Closed access
EMEmil Ivanov Manov
Emil Ivanov Manov
VPVentsislava Pencheva Pencheva
Ventsislava Pencheva Pencheva
NRNikolay Runev
Nikolay Runev
SNStefan Naydenov
Stefan Naydenov
DSDaniela Stoychkova
Daniela Stoychkova
Background: Pericardial effusion in chronic hypoxemic lung diseases such as obstructive sleep apnea syndrome usually occurs after the development of severe pulmonary arterial hypertension. However, data about the frequency of pericardial effusions in obstructive sleep apnea syndrome without pulmonary arterial hypertension and/or day-time hypoxemia are still scarce and their pathogenesis is unclear. Aims: To assess the prevalence of pericardial effusions, their volume and location in patients with obesity and obstructive sleep apnea syndrome without pulmonary arterial hypertension and/or hypoxemia. Study Design: Cross-sectional study. Methods: We included 279 consecutive patients (162 males) with newly diagnosed obstructive sleep apnea syndrome, mean age 42.8±12.4 years, mean body mass index 37.3±7.8 kg/m2. Obstructive sleep apnea syndrome was confirmed by polysomnography. Main exclusion criteria were as follows: Concomitant inflammatory diseases, thyroid dysfunction, day-time hypoxemia, nephrotic syndrome, left ventricular systolic dysfunction and pulmonary arterial hypertension. Results: Pericardial effusion was found in 102 (36.56%) - all of them with moderate to severe obstructive sleep apnea syndrome. The mean effusion volume was mild to moderate (up to 250 mL). In 36 patients (35.3%) the pleural effusion was diffuse, in 42 (41.2%) - located in front of the right atrium and the right ventricle and in 24 (23.5%) - in front of the right cardiac cavities and the left atrium. We found significant positive correlation between presence of pericardial effusion and: Apnea-hypopnea index (r=0.374, p<0.001), body mass index (r=0.473, p<0.001), desaturation time during sleep (r=0.289, p<0.001). Conclusion: Pericardial effusion in patients with obesity and moderate to severe obstructive sleep apnea syndrome without daily hypoxemia and/or pulmonary hypertension is a relatively common finding. Occurrence of pericardial effusions is dependent mostly on the obstructive sleep apnea syndrome grade, the degree of obesity and the duration of sleep desaturation.

1 May 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
NRNikolay Runev
Nikolay Runev
SDStamen Mitev Dimitrov
Stamen Mitev Dimitrov